A 36-month, open-label, prospective, observational study of paliperidone palmitate in patients with severe schizophrenia

Trial Profile

A 36-month, open-label, prospective, observational study of paliperidone palmitate in patients with severe schizophrenia

Completed
Phase of Trial: Phase IV

Latest Information Update: 11 Nov 2016

At a glance

  • Drugs Paliperidone (Primary)
  • Indications Schizophrenia
  • Focus Adverse reactions
  • Most Recent Events

    • 11 Nov 2016 New trial record
    • 06 Oct 2016 Results published in the International Clinical Psychopharmacology.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top